Late Breaking-Disease-modifying therapy

Late Breaking-Disease-modifying therapy

Humoral and T-Cell Responses to Sars-Cov-2 Vaccination in Multiple Sclerosis Patients Treated with Ocrelizumab

Background: The COVID-19 epidemic raises important questions about the efficacy of vaccines for people treated with ocrelizumab (OCR), an...

Read More